SOLIGENIX, INC. Foreign Income Tax Expense (Benefit), Continuing Operations
SOLIGENIX, INC. (SNGX) reported Foreign Income Tax Expense (Benefit), Continuing Operations of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-15.
Discontinued › Expense Statement › Income Tax
us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations · last filed 2024-03-15
- SOLIGENIX, INC. foreign income tax expense (benefit), continuing operations for fiscal 2023 was $0.00.
- SOLIGENIX, INC. foreign income tax expense (benefit), continuing operations for fiscal 2022 was $0.00.
- SOLIGENIX, INC. foreign income tax expense (benefit), continuing operations for fiscal 2021 was $0.00.
- SOLIGENIX, INC. foreign income tax expense (benefit), continuing operations for fiscal 2020 was $0.00.
| Period end | Foreign Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-15 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-15 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |